CA2311126A1 - Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration - Google Patents

Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration Download PDF

Info

Publication number
CA2311126A1
CA2311126A1 CA002311126A CA2311126A CA2311126A1 CA 2311126 A1 CA2311126 A1 CA 2311126A1 CA 002311126 A CA002311126 A CA 002311126A CA 2311126 A CA2311126 A CA 2311126A CA 2311126 A1 CA2311126 A1 CA 2311126A1
Authority
CA
Canada
Prior art keywords
formula
represents hydrogen
use according
radical
benzenesulphimidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002311126A
Other languages
English (en)
French (fr)
Inventor
Thomas Fahrig
Irene Gerlach
Ervin Horvath
Reinhard Jork
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2311126A1 publication Critical patent/CA2311126A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
CA002311126A 1997-11-24 1998-11-11 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration Abandoned CA2311126A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19751949.0 1997-11-24
PCT/EP1998/007197 WO1999026621A1 (de) 1997-11-24 1998-11-11 Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration

Publications (1)

Publication Number Publication Date
CA2311126A1 true CA2311126A1 (en) 1999-06-03

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002311126A Abandoned CA2311126A1 (en) 1997-11-24 1998-11-11 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration

Country Status (30)

Country Link
US (2) US6235774B1 (enExample)
EP (1) EP1051170B1 (enExample)
JP (1) JP2001523716A (enExample)
KR (1) KR20010032357A (enExample)
CN (1) CN1134256C (enExample)
AR (1) AR016973A1 (enExample)
AT (1) ATE206615T1 (enExample)
AU (1) AU745759B2 (enExample)
BG (1) BG64167B1 (enExample)
CA (1) CA2311126A1 (enExample)
DE (2) DE19751949A1 (enExample)
DK (1) DK1051170T3 (enExample)
ES (1) ES2164465T3 (enExample)
HN (1) HN1998000169A (enExample)
HU (1) HUP0004369A3 (enExample)
IL (1) IL135904A (enExample)
IS (1) IS5496A (enExample)
MY (1) MY118414A (enExample)
NO (1) NO20002638L (enExample)
NZ (1) NZ504656A (enExample)
PE (1) PE134999A1 (enExample)
PL (1) PL340674A1 (enExample)
PT (1) PT1051170E (enExample)
RU (1) RU2217140C2 (enExample)
SI (1) SI1051170T1 (enExample)
SV (1) SV1998000138A (enExample)
TR (1) TR200001471T2 (enExample)
TW (1) TW524690B (enExample)
WO (1) WO1999026621A1 (enExample)
ZA (1) ZA9810668B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
AU2002355170B2 (en) * 2001-07-26 2007-06-07 Merck Patent Gmbh Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
ATE341322T1 (de) * 2001-09-12 2006-10-15 Merck Patent Gmbh Verwendung von aminomethyl chromanen zur behandlung der nebenwirkungen von neuroleptika
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
ES2996835T3 (en) 2016-07-29 2025-02-13 Sumitomo Pharma America Inc Compounds and compositions and uses thereof
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
AU2018312559B2 (en) * 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
WO2020186165A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE19522088A1 (de) 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
DE59801724D1 (de) 2001-11-15
NO20002638D0 (no) 2000-05-23
TW524690B (en) 2003-03-21
CN1279604A (zh) 2001-01-10
EP1051170A1 (de) 2000-11-15
NO20002638L (no) 2000-05-23
IS5496A (is) 2000-05-15
AU745759B2 (en) 2002-03-28
US6235774B1 (en) 2001-05-22
ES2164465T3 (es) 2002-02-16
CN1134256C (zh) 2004-01-14
ATE206615T1 (de) 2001-10-15
AR016973A1 (es) 2001-08-01
JP2001523716A (ja) 2001-11-27
BG104466A (en) 2001-02-28
HUP0004369A3 (en) 2002-04-29
MY118414A (en) 2004-10-30
IL135904A0 (en) 2001-05-20
HN1998000169A (es) 1999-11-03
HUP0004369A2 (hu) 2001-04-28
SV1998000138A (es) 1999-05-25
PT1051170E (pt) 2002-02-28
US6331561B2 (en) 2001-12-18
NZ504656A (en) 2002-02-01
KR20010032357A (ko) 2001-04-16
TR200001471T2 (tr) 2000-10-23
PE134999A1 (es) 2000-03-05
DE19751949A1 (de) 1999-05-27
EP1051170B1 (de) 2001-10-10
US20010018530A1 (en) 2001-08-30
DK1051170T3 (da) 2001-12-27
SI1051170T1 (en) 2001-12-31
PL340674A1 (en) 2001-02-12
IL135904A (en) 2003-07-06
BG64167B1 (bg) 2004-03-31
ZA9810668B (en) 1999-05-26
WO1999026621A1 (de) 1999-06-03
AU1668599A (en) 1999-06-15
RU2217140C2 (ru) 2003-11-27

Similar Documents

Publication Publication Date Title
US6235774B1 (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
US20250268858A1 (en) Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep
CA1238280A (en) Pharmaceutical compositions containing bilobalid
AU782344B2 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US20090042972A1 (en) Methods of using low-dose doxepin for the improvement of sleep
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
US4491594A (en) Method for treatment of seizures
EP2286819B1 (en) Pharmaceutical composition for treating cardio-cerebro vascular diseases and preparative method and kit thereof
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
EP3804705B1 (en) Pharmaceutical composition for preventing diabetes and use thereof
HK1034661A (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
MXPA00005054A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
JP2807535B2 (ja) 白内障治療剤
JPH1053526A (ja) 医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued